CClinicalTrials.gg
Status unknownNCT03377920Updated Dec 19, 2017

Predictive Value of Spirometric PIF to Produce PIF Rate Needed for the Use of Current DPI's.

An interventional study of In-check Dial device (Clement Clarke International Ltd, Harlow, UK) in Severe Asthma and COPD, sponsored by Universitair Ziekenhuis Brussel. Status unknown at 1 site in Belgium. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2017-12-19.

Sponsored by Universitair Ziekenhuis Brussel · Not applicable, Interventional, and Other

The sponsor has not verified this record recently (last verified Oct 2017), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
21 Years and older
Sex
All
01

Study summary

The main aim is to study correlations between Peak inspiratory flow measured during a spirometry (PIFspiro) and Peak inspiratory flow measured over a pre-set resistance (PIFresist) in COPD patients and severe asthma patients. PIFresist will be measured using 5 different resistances, representing all DPI's relevant for the treatment of obstructive lung diseases. If this shows a distinct relationship between PIFspiro and PIFresist, PIFspiro cut-off points will be sought in an attempt to predict which patients are likely to be able to produce optimal flows for DPI use. If successful, this will make the actual measurement of PIFresist redundant in clinical practice. Also the relationship between PIFresist and device internal resistance in addition to PIFspiro (which corresponds to a very low resistance) will be examined.

Read the detailed description

The correct use of dry powder inhalers (DPI) crucially depends on the peak inspiratory flow (PIF) that the patient can generate when overcoming internal resistance of the inhaler device.

It has been shown that some patients cannot achieve sufficient peak inspiratory flows with some DPI's, especially in the elderly population. The In-check Dial device (Clement Clarke International Ltd, Harlow, UK) allows to measure these inspiratory flows for different pre-set resistances, representing different DPI's.

Study design: interventional, single center, single visit study

30 Severe asthmatics and 70 COPD patients will be recruited in the UZ Brussel respiratory outpatient clinic.

All participants will provide written informed consent.

Patients will perform:

  • pre-bronchodilator spirometry for the measurement of PIFspiro as per European respiratory Society/American Thoracic Society (ERS/ATS) guidelines for standard lung function5 (part of routine clinical follow-up).
  • 5 forced inspiratory manoeuvres using the In-check Dial device G16, set at 5 different resistances (performed in order of increasing resistance), yielding the PIFresist values for the different DPI's
02

Conditions studied

  • Severe Asthma
  • COPD
03

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Severe asthmatics (M/F; > 20 y) entering the Belgian Severe Asthma Registry (BSAR)
  • COPD patients (GOLD stage II-IV; M/F; > 40 y)

Exclusion criteria

Exclusion Criteria:

  • Inability to perform spirometry
04

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Severe asthma patients; COPD patients

    Cross sectional study Lung function measurement

    Device: In-check Dial device (Clement Clarke International Ltd, Harlow, UK)

Interventions

  • DeviceIn-check Dial device (Clement Clarke International Ltd, Harlow, UK)

    * pre-bronchodilator spirometry for the measurement of PIFspiro as per ERS/ATS guidelines for standard lung function5 (part of routine clinical follow-up). * 5 forced inspiratory manoeuvres using the In-check Dial device G16, set at 5 different resistances (performed in order of increasing resistance), yielding the PIFresist values for the different DPI's

05

What researchers measure

Primary outcomes

  1. PIFspiro

    PIFspiro (L/s): PIF measurement from standardized spirometry (3 flow-volume measurements);

    Time frame: At inclusion (D0)

  2. PIFresist

    PIFresist (L/min): PIF from In-check Dial (5 flow measurements with flow restrictor in 5 different positions)

    Time frame: At inclusion (D0)

06

Study locations

1 of 1 sites recruiting
  • UZ Brussel
    Brussel, 1090, Belgium
    • Anja Baeten · Contact
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03377920
Lead sponsor
Universitair Ziekenhuis Brussel
Responsible party
Sponsor
First posted
Dec 19, 2017
Start date
Oct 12, 2017
Primary completion
Sep 2019 (estimated)
Completion
Sep 2019 (estimated)
Last update
Dec 19, 2017

Study contacts

Shane Hanon
Contact
shane.hanon@uzbrussel.be
00324776841
Shane Hanon
principal investigator · Universitair Ziekenhuis Brussel

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion